A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
To explore the efficacy and safety of Culmerciclib combined with chemotherapy as neoadjuvant therapy for HR+/HER2- breast cancer patients who are insensitive to neoadjuvant TAC (docetaxel, doxorubicin, cyclophosphamide) chemotherapy.
Epistemonikos ID: 24acef254f06b5b8b4c6c9f3f5037c7cd4d1a1f0
First added on: Oct 29, 2026